Scancell appoints new heads of research and manufacturing
21st Jan 2019 12:30
(Sharecast News) - Immunotherapy developer Scancell Holdings announced the appointment of Dr Samantha Paston as its head of research, and Dr Adrian Parry as its head of manufacturing, on Monday.
Read moreScancell pleased with progress on 'Moditope' vaccines
30th Oct 2018 14:36
(Sharecast News) - Novel immunotherapies developer Scancell Holdings updated the market on the development of its second vaccine from its proprietary 'Moditope' platform, Modi-2, on Tuesday, reporting that pre-clinical data demonstrated that homocitrullinated peptides induced highly potent T-cell responses, tumour rejection and increased survival in murine models.
Read moreScancell to develop ImmunoBody lung cancer treatment
10th Oct 2016 11:42
(ShareCast News) - Cancer immunotherapy development company Scancell Holdings announced on Monday its intention to develop its SCIB2 ImmunoBody for the treatment of non-small cell lung cancer in combination with a checkpoint inhibitor. The AIM-traded firm's board approved the decision based on the o
Read moreScancell Holdings widens full year loss on US investment
16th Sep 2016 14:24
(ShareCast News) - Scancell Holdings, a developer of novel immunotherapies for the treatment of cancer, has reported a third consecutive full year loss due to the costs involved in its expansion in the US. The firm has seen a 3% increase in its operating loss over the last three years. The loss was
Read moreScancell granted product licence extension from Ichor Medical Systems
20th Jul 2016 12:35
(ShareCast News) - Scancell, the developer of immunotherapies for cancer treatments, was granted a product licence option extension from Ichor Medical Systems. The extension is to licence the commercial use of Ichor's TriGrid electroporation delivery system with SCIB1, Scancell's ImmunoBody vaccine,
Read moreScancell suspends dosing with current supplies of SCIB1 for melanoma
17th Jun 2016 12:24
(ShareCast News) - Shares in drug developer Scancell Holdings plunged almost 17% after it suspending dosing with current clinical trial supplies of SCIB1 for melanoma with immediate effect. Patients would be notified as soon as possible. AIM-quoted Scancell said quality-control analysis showed the
Read moreScancell raises £6.2m in placing and open offer
4th Apr 2016 11:47
(ShareCast News) - Scancell revealed the final results of its placing and open offer on Monday, with a few more subscriptions received since the firm's last update on 1 April. The AIM-traded company had announced on Friday that it had received subscriptions for 16,048,593 new ordinary shares of the
Read moreScancell skips higher on Swedish research collaboration
11th Mar 2016 08:51
(ShareCast News) - Immuno-oncology specialist Scancell has impressed investors with a new research partnership with Sweden's Karolinska Institutet into the role of citrullinated proteins in the treatment of cancer. Both parties have uncovered important roles that citrullinated proteins can play in h
Read moreBigger loss but positive drug trial results for Scancell Holdings
18th Sep 2015 09:23
(ShareCast News) - Scancell Holdings's losses increased marginally in the year ended 30 April 2015. The cancer immunotherapy developer announced on Friday a wider loss of £2.414m from £2.222m last year. It comes as a result of expected additional expenditure on its SCIB1 ImmunoBody clinical trials
Read moreScancell gives positive update on melanoma treatment data
2nd Jun 2015 12:19
Biopharmaceutical company Scancell Holdings reported further encouraging results from the ongoing 'Phase 1/2' clinical trial of its melanoma treatment SCIB1, which it presented at the annual meeting of the American Society of Clinical Oncology in Chicago. The data showed that all 16 patients with re
Read moreScancell Holdings sees annual losses widen
4th Sep 2014 11:23
Scancell Holdings, a developer of novel immunotherapies for the treatment of cancer, made an annual loss of £2.22m in the year to 30 April compared to £1.9m last year. The company development spending increased due to additional costs in pre-clinical studies for a new platform technology, while adm
Read moreScancell Holdings ImmunoBody technology receives US approval
6th Jun 2014 08:54
AIM-listed Pharmaceuticals group Scancell Holdings announced a patent for its DNA ImmunoBody technology has been approved in the US. The patent has been granted by the United States Patent and Trademark Office (USPTO) and covers Scancell's DNA ImmunoBody platform technology. This patent is expect
Read moreScancell reports encouraging results of melanoma treatment
2nd Jun 2014 11:08
Scancell's shares advanced after announcing "encouraging results" from the clinical trial of its SCIB1 ImmunoBody drug for the treatment of stage III/IV melanoma. The phase 1 and 2 trial tested the safety and tolerability of four dose levels of SCIB1 administered intramuscularly using an electropo
Read morePrezzo exec slices off 200,000 shares
22nd Oct 2013 16:26
Kuldip Sehmi, an Executive Director at Italian restaurant chain Prezzo, on Monday traded in 200,000 shares, reducing his stake to 682,244 shares, equal to 0.29 per cent of the issued share capital. Sehmi, who is responsible for the day to day running of approximately half the Prezzo estate, sold t
Read moreScancell reports progress across a number of trials
1st Oct 2013 10:02
Scancell, which develops novel immunotherapies for the treatment of cancer, on Tuesday revealed that four out of the six evaluable patients treated with either the 2mg or 4mg dose of its SCIB1 drug still remain alive. It said the mean survival time in this group of five Stage IV and one Stage IIIb
Read more